Goldman Sachs Group Inc. Has $173.87 Million Holdings in Exelixis, Inc. (EXEL)
Goldman Sachs Group Inc. boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 13.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,059,232 shares of the biotechnology company’s stock after acquiring an additional 818,782 shares during the quarter. Goldman Sachs Group Inc. owned about 2.40% of Exelixis worth $173,869,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of EXEL. First Quadrant L P CA bought a new position in Exelixis during the second quarter valued at $144,000. Meeder Asset Management Inc. purchased a new stake in shares of Exelixis in the first quarter valued at $170,000. Wetherby Asset Management Inc. bought a new stake in shares of Exelixis in the 2nd quarter worth about $218,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Exelixis in the 1st quarter worth about $236,000. Finally, Capstone Asset Management Co. bought a new stake in shares of Exelixis in the 2nd quarter worth about $242,000. 79.20% of the stock is currently owned by institutional investors.
A number of equities analysts recently commented on the stock. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Cowen and Company reissued an “outperform” rating on shares of Exelixis in a research report on Thursday, August 10th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price objective on the stock in a research report on Tuesday, July 4th. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $26.00 price objective on shares of Exelixis in a research note on Thursday, September 7th. Six analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Exelixis currently has an average rating of “Buy” and an average price target of $29.50.
Shares of Exelixis, Inc. (NASDAQ EXEL) traded down 0.70% during midday trading on Monday, reaching $24.06. 915,060 shares of the company were exchanged. Exelixis, Inc. has a 52 week low of $10.04 and a 52 week high of $29.50. The firm has a 50-day moving average of $27.08 and a 200 day moving average of $23.49. The firm has a market capitalization of $7.07 billion, a P/E ratio of 121.52 and a beta of 1.92.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company had revenue of $99.01 million for the quarter, compared to the consensus estimate of $85.27 million. During the same quarter in the previous year, the business earned ($0.15) earnings per share. The company’s revenue for the quarter was up 173.1% on a year-over-year basis. On average, equities research analysts expect that Exelixis, Inc. will post $0.27 EPS for the current year.
In related news, insider Michael Morrissey sold 300,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $26.90, for a total value of $8,070,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $26.79, for a total transaction of $2,679,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 970,152 shares of company stock worth $25,923,457. Corporate insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.